Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1

• Register: ClinicalTrials.gov
• Last refreshed on: 8 November 2021
• Main ID: NCT03887533
• Date of registration: 22/03/2019
• Prospective Registration: Yes
• Primary sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Public title: Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1
• Scientific title: Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1
• Date of first enrolment: January 6, 2020
• Target sample size: 2
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03887533
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1/Phase 2

Countries of recruitment

United States

Contacts

• Name: Forbes D Porter, M.D.
• Affiliation: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Key inclusion & exclusion criteria

-INCLUSION CRITERIA:

1. Age greater than or equal to 3 and less than or equal to 60 years old at time of
enrollment

2. Diagnosis of NPC1 based upon one of the following:

A. Two NPC1 mutations

B. Biochemical Positive for NPC (oxysterol/bile acid and sphingomyelinase levels
consistent with a diagnosis of NPC) and one NPC1 mutation

- NPC1 mutations will be interpreted using standards established for the
interpretation of sequence variants [33].

- Oxysterol/Bile Acid testing refers to cholestane-3beta,5 ,6beta-triol [7, 8] or
3beta,5alpha,6beta-trihydroxycholanic acid and its glycine conjugate [34].

3. Evidence of NPC1-related liver disease as defined by one of the following:

A. Abnormal liver chemistries as defined by one of the following:

i. Plasma aspartate aminotransferase (AST) greater than or equal to 1.5-times
age-appropriate upper limit of normal

ii. Plasma aspartate aminotransferase (AST) greater than or equal to 1.25-times
age-appropriate upper limit of normal and plasma alanine aminotransferase (ALT) >
1.25-times age-appropriate upper limit of normal

iii. Plasma aspartate aminotransferase (AST) greater than or equal to 1.25-times
age-appropriate upper limit of normal and AST/ALT ratio greater than or equal to 2.0 AND
Abnormal liver chemistries as defined above at least 8 weeks apart.

B. Abnormal Liver Ultrasound* defined as one of the following:

1. Intraparenchymal echogenic bands consistent with fibrosis

2. Abnormal liver echogenicity with AST or ALT above the upper limit of normal.

3. Hepatomegaly with AST or ALT above the upper limit of normal.

To define hepatomegaly, we will use the suggested limit of normal of the longitudinal
dimension of the right lobe of the liver. These values are approximately 2 standard
deviations above the mean.

C. Abnormal liver stiffness (FibroScan**) for age.

To define Liver Stiffness Measurement we will use the normal age dependent ranges.
Values above the 95th centile will be considered abnormal.

4. Ability to travel to the NIH Clinical Center repeatedly for evaluation and follow-up.

5. Willingness to discontinue all non-prescription supplements, except for an
age-appropriate multivitamin/mineral supplement.

6. Stable miglustat dose for 3 months prior to entry into the IV portion of the trial.

7. Women of reproductive age must be willing to use an effective method of contraception
for the duration of the trial if sexually active.

8. Willingness to participate in all aspects of the IV trial

EXCLUSION CRITERIA:

- Age <3 or > 60 years of age at time of enrollment in the trial.

- Subjects who have received any form of parenteral cyclodextrin, an HDAC inhibitor, or
an experimental therapy for NPC in the prior six months. Prior Intrathecal VTS-270
treatment is allowed.

- History of hypersensitivity reactions to cyclodextrin or components of the
formulation.

- Pregnancy or breastfeeding. Females of childbearing potential unwilling to utilize a
highly effective form of contraception (i.e., barrier method with spermicide,
intrauterine device, steroidal contraceptive in conjunction with a barrier method, or
abstinence if it is the patient s baseline preference) for the duration of the study
and for 30 days after participation.

- Any systemic infection at the time of enrollment.

- Neutropenia, defined as an absolute neutrophil count (ANC) of less than 1,500 per
microliter. Subjects with benign cyclic/ethnic neutropenia may be enrolled if not
clinically symptomatic.

- Thrombocytopenia defined as a platelet count less than 75,000 per microliter.

- Established history of a chronic clotting or bleeding disorder.

- Use of anticoagulants within 3 months of enrollment

- Severe or acute liver disease as defined by one of the following:

A. AST or ALT greater than 10-times age-appropriate upper limit of normal

B. Jaundice or right upper quadrant pain

C. INR >1.8

- Individuals with AST and ALT greater than 4-times the age-appropriate upper limit of
normal will be excluded if they have a positive NIH Clinical Center Viral Markers
Hepatitis Screen (HBsAG, anti-HCV and Anti-HAV IgM). This screening test will not be
obtained unless AST and ALT are elevated. An equivalent panel from another laboratory
may be used if this elevation is noted on screening. Individuals excluded under this
criterion may be rescreened after the acute pathology resolves (e.g. Hepatitis A
infection).

- Presence of anemia defined as two standard deviations below normal for age and gender.

- Serum creatinine level greater than 1.5 times the age-appropriate upper limit of
normal OR FOR INDIVIDUALS >= 6 years of age an eGRF < 60 mL/min 1.73 m squared

- Hematuria on a single urinalysis, as defined by the American Urological Association
(AUA) as five or more red blood cells per high-power field on microscopic evaluation
of urinary sediment from a properly collected urinalysis specimen. The patient will
not be excluded if two subsequent urine specimens are negative for hematuria as
defined by the AUA.

- Proteinuria (1+ protein on repeat urinalysis) unless evaluated and classified as
benign.

- Active pulmonary disease, oxygen requirement or clinically significant history of
decreased blood oxygen saturation (SaO2 <95% on room air), pulmonary therapy, daily
use of a cough assist device or pulmonary vest, requiring active suction, or with a
tracheostomy.

- Patients with uncontrolled seizures per either of the criteria below.

1. Unstable frequency, type or duration of seizures. Quantified by a seizure log
over one month prior to enrollment.

2. Subject requiring antiepileptic medication changes (other than dose adjustments
for weight) in the month prior to enrollment.

- Individuals receiving parenteral nutrition will be excluded.

- Patients, who in the opinion of the investigators, are unable to comply with the
protocol or have specific health concerns that would potentially increase the risk of
participation.

Additional exclusion criteria for intrathecal VTS-270

1. Neurologically asymptomatic. Determination made by the investigators based on history,
neurological exam and consultant input.

2. Suspected infection of the central nervous system

3. Spinal deformity that would impact the ability to perform a lumbar puncture

4.


Age minimum: 3 Years
Age maximum: 60 Years
Gender: All

Health Condition(s) or Problem(s) studied

Niemann-Pick Disease, Type C1

Intervention(s)

Drug: VTS-270

Primary Outcome(s)

Safety and Tolerabilty [Time Frame: one-year]

Secondary Outcome(s)

plasma Cholestane-3B,5a,6B-triol [Time Frame: One-year]

Secondary ID(s)

19-CH-0028

190028

Source(s) of Monetary Support

Please refer to primary and secondary sponsors